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Abstract
Background: Multiple sclerosis is a demyelinating disease mostly of autoimmune origin that affects and damages
the central nervous system, leading to a disabling condition. The aim of the present study was to investigate
whether administration of mesenchymal stem cells from human periodontal ligament (hPDLSCs) could ameliorate
multiple sclerosis progression by exerting neuroprotective effects in an experimental model of autoimmune
encephalomyelitis (EAE).
Methods: EAE was induced by immunization with myelin oligodendroglial glycoprotein peptide (MOG)35–55 in
C57BL/6 mice. After immunization, mice were observed every 48 hours for signs of EAE and weight loss. At the
onset of disease, approximately 14 days after immunization, EAE mice were subjected to a single intravenous
injection of hPDLSCs (106 cells/150 μl) into the tail vein. At the point of animal sacrifice on day 56 after EAE
induction, spinal cord and brain tissues were collected in order to perform histological evaluation,
immunohistochemistry and western blotting analysis.
Results: Achieved results reveal that treatment with hPDLSCs may exert neuroprotective effects against EAE,
diminishing both clinical signs and histological score typical of the disease (lymphocytic infiltration and
demyelination) probably through the production of neurotrophic factors (results focused on brain-derived
neurotrophic factor and nerve growth factor expression). Furthermore, administration of hPDLSCs modulates
expression of inflammatory key markers (tumor necrosis factor-α, interleukin (IL)-1β, IL-10, glial fibrillary acidic
protein, Nrf2 and Foxp3), the release of CD4 and CD8α T cells, and the triggering of apoptotic death pathway
(data shown for cleaved caspase 3, p53 and p21).
Conclusions: In light of the achieved results, transplantation of hPDLSCs may represent a putative novel and
helpful tool for multiple sclerosis treatment. These cells could have considerable implication for future therapies for
multiple sclerosis and this study may represent the starting point for further investigations.
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Background
Multiple sclerosis (MS) is a chronic inflammatory and
demyelinating disease of the central nervous system
(CNS). In northern industrialized countries, MS affects
about 0.1 % of the population and is the first cause of
disability of non-traumatic origin in young adults [1].
The etiology of MS is still incompletely understood;
however, it seems that the main etiopathogenic event is
represented by an unusual response of the immune sys-
tem cells (T and B lymphocytes) against myelin sheaths
of neurons [2].
To date, current treatments for MS only offer pallia-
tive relief without providing a cure, and many are also
associated with adverse effects that limit their long-term
utility [3].
Recently, the potential role of mesenchymal stem cells
(MSCs), derived especially from bone marrow, in pro-
moting tissue repair and disease control has been inves-
tigated by using an experimental autoimmune
encephalomyelitis (EAE) model [4–7], the most common
animal model that mimics the main features of human
MS [8].
It is well known that MSCs can differentiate under
certain circumstances, giving rise to various neuronal
and glial cell lineages [9]. Also, MSC transplantation is
able to modulate the immune system at CNS lesions and
enhances remyelination and the repairing process [10, 11].
However, the defined immunomodulatory mechanisms by
which these cells exert their regulatory activities have not
been clarified yet. It is probable that neuroprotective ef-
fects may result from release of anti-apoptotic proteins as
well as neurotrophic factors [12, 13].
Although the therapeutic efficacy of these cells has
been widely proven, we looked to an alternative source
of stem cells that could be less invasive for removal. In
this regard the mesenchymal stem cells derived from the
oral cavity and in particular from human periodontal
ligament (hPDLSCs) may represent a very promising
source.
The hPDLSCs are isolated from the periodontium, a
tissue of ectomesenchymal origin that is particularly well
adapted to different functions; it supports the teeth in
their sockets and at the same time permits withstanding
the considerable forces of mastication. In particular, the
periodontium tissue contains cell islands called epithelial
rests of Malassez regulating the growth induction of
nerve endings [14].
The hPDLSCs originate from cranial neural crest cells,
a transient embryonic structure, composed of migratory
and multipotent stem cells that provide a wide variety of
cell phenotypes including peripheral neurons, Schwann
cells, and vascular smooth muscle cells. They represent
an available niche of MSCs that can be obtained with re-
stricted morbidity and without additional risks to the
donor using minimally invasive periodontal access flap
surgery [15–18]. The hPDLSCs can differentiate under
appropriate stimuli into mesenchymal tissues such as
bone, cartilage, fat and into neurogenic lineage [18–21].
With regard to the neuronal differentiation, many
studies have reported on the successes of in vitro forma-
tion of neuronal lineage cells from PDLSCs [20, 22] and
in particular it has also been shown that untreated oral
stem cells were able to differentiate into functional neu-
rons upon injection into the developing avian nervous
system [23].
Furthermore, the hPDLSCs express proteins impli-
cated in the cell cycle regulation and stress response,
homing, detoxification, neurogenesis and neuronal func-
tion homeostasis suited for their neural crest origin [24].
Moreover, in addition to their self-renewal potential and
multilineage differentiation ability, dental MSCs possess
potent immunomodulatory functions and a higher cap-
ability of cell growth in comparison to bone marrow-
derived MSCs, representing a new stem cell niche for
translational medicine [25, 26].
This study aimed to investigate the possible neuropro-
tective effect of hPDLSC administration against the
overall cascade of events occurring after EAE induction




The protocol and informed consent from human peri-
odontal ligament biopsies were approved by the Medical
Ethics Committee at the Medical School, “G. d’Annunzio”
University, Chieti, Italy (n°266/17.04.14). The formal con-
sent form was signed by the subjects (range age 20–35
years) before specimen collection. The Department of
Medical, Oral and Biotechnological Sciences and the
Laboratory of Stem Cells and Regenerative Medicine
are certified according to the quality standard ISO
9001:2008 (certificate n° 32031/15/S).
Isolation and culture of hPDLSCs
Five human periodontal ligament biopsies were scraped
from human premolar teeth that were due to be removed
for orthodontic treatment in healthy patients. The peri-
odontal ligament tissue was obtained by grating the roots
using the Gracey’s curette [18]. The samples were washed
five times with phosphate-buffered saline (PBS; LiStar-
Fish), and cultured using TheraPEAK™MSCGM-CD™
BulletKit serum free, which was chemically defined
(MSCGM-CD) medium for the growth of human MSCs
(Lonza, Basel, Switzerland). The medium was changed
twice a week, and cells migrating from the explant tissue
after reaching about 80 % confluence were trypsinized
(LiStar Fish) and subcultured until passage 2.
Trubiani et al. Stem Cell Research & Therapy  (2016) 7:1 Page 2 of 15
hPDLSC immunophenotyping
hPDLSCs at the second passage were collected; 5 × 105
cells per sample were incubated with 1 μg of the specific
antibody, conjugated with fluorescein isothiocyanate,
phycoerythrin, allophycocyanin, phycoerythrin-cyanine
5.5, or Alexa Fluor 488 for 30 min at 4 °C in the dark.
hPDLSCs were stained using the following antibodies:
anti-CD13, anti-CD29, anti-CD44, anti-CD45, anti-
CD105, anti-CD166 (Ancell, MN, USA), anti-CD14,
anti-CD133 (BergischGladbach, Germany), anti-CD73,
anti-CD90, anti-CD117, anti-CD146, anti-CD271, anti-
Sox2, anti-HLA-DR, anti-SSEA4, anti-OCT3/4 (Becton
Dickinson, BD, San Jose, CA, USA), anti-CD144 (Acris
Antibodies, Herford, Germany) and anti-CD34 (Beckman
Coulter, Fullerton, CA, USA). After incubation, cells were
acquired with a flow cytometer (FACS Calibur; BD). Data
were analyzed by the FlowJo software v8.8.6 (TreeStar,
Ashland, OR, USA) [17].
Morphological analysis
Glass-adherent hPDLSCs at passage 2 were fixed with
2.5 % glutaraldehyde in 0.1 M cacodylate buffer, pH7.4,
for 2 h, and were subsequently stained with toluidine
blue and observed by light microscopy. All sections were
observed with a Zeiss Axiophot apparatus, and images
captured using a Nikon digital camera Digital Sight.
MTT assay
The viability of hPDLSC culture was analyzed by the quan-
titative colorimetric MTT (3-[4,5-dimethyl-2-thiazolyl]-
2,5-diphenyl-2Htetrazoliumbromide test) (Promega, Milan,
Italy). Cells (2 × 103 cells/well) were seeded into a 96-well
culture plate with MSCGM-CD, and the supernatants were
read at 650 nm wavelength using a ND-1000 NanoDrop
Spectrophotometer (NanoDrop Technologies, Rockland,
DE, USA). The MTT assay was performed in five inde-
pendent experiments, one for each donor, with five repli-
cates for each experimental point.
Mesengenic differentiation and histochemical analysis
For osteogenic and adipogenic differentiation, hPDLSCs
at passage 2 were incubated in MSCGM-CD (Lonza)
medium with osteogenic supplements and in adipogene-
sis induction/maintenance medium (Lonza), respectively.
Osteogenic and adipogenic induction was confirmed by
means of colorimetric assay as previously described by
Trubiani et al. [17]. hPDLSCs for chondrogenic differen-
tiation at passage 2 were transferred into 15 mL poly-
propylene tubes and centrifuged at 800 rpm for 8 min to
obtained pellets at the bottom of the tube. A pellet was
incubated in hMSC Chondro Bullet Kit (Lonza) with
added transforming growth factor β3, as described by
Yang et al. [27]. The pellets were fixed in 4 % parafor-
maldehyde at 4 °C for 24 h, dehydrated in an ascending
series of ethanols (40, 70, 90 and 100 % ethanol; 20 min/
step) and embedded in paraffin. Sections (3 μm) were
cut and stained with 1 % Alcian blue (pH2.5; Sigma
Aldrich, Milan, Italy) for 5 min and observed by
means of light microscopy. The differentiation process
was performed in five separate experiments using
hPDLSCs derived from five different donors.
RNA isolation and real time-PCR analysis
Osteogenic and adipogenic markers were evaluated by
real-time polymerase chain reaction (PCR). To this end,
total RNA was isolated using the Total RNA Purification
Kit (NorgenBiotek Corp., Ontario, CA, USA) according
to the manufacturer’s instructions. The M-MLV Reverse
Transcriptase reagents (Applied Biosystems) were used
to generate cDNA. Real-Time PCR was carried out with
the Mastercycler ep realplex real-time PCR system
(Eppendorf, Hamburg, Germany). hPDLSC expression of
Runt-related transcription factor-2 (RUNX-2) and alka-
line phosphatase (ALP) was evaluated after 7 days in
osteogenic differentiated culture. The expression of fatty
acid binding protein 4 (FABP4) and peroxisome prolif-
erator-activated receptor γ (PPARγ) were analyzed after
28 days of adipogenic differentiation culture. Aggrecan
(ACAN) and collagen type II (COL2A1) expression were
evaluated after 28 days of chondrogenic induction. Com-
mercially available TaqMan Gene Expression Assays
(RUNX-2 Hs00231692_m1; ALP Hs01029144_m1; FABP4
Hs01086177_m1; PPARγ Hs01115513_m1; ACAN
Hs00153936_m1; COL2A1 Hs00264051_m1) and the Taq-
Man Universal PCR Master Mix (Applied Biosystems,
Foster City, CA, USA) were used according to standard
protocols. Beta-2 microglobulin (B2M Hs99999907_m1)
(Applied Biosystems, Foster City, CA, USA) was used for
template normalization. Real-time PCR was performed in
three independent experiments, and duplicate determina-
tions were carried out for each sample.
Animals
Male C57BL/6 mice (Harlan, Milan, Italy), 12 weeks of
age and weighing 20–25 g, were housed in individually
ventilated cages with food and water ad libitum. The
room was maintained at a constant temperature and hu-
midity with a 12 h/12 h light/dark cycle.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the guide for the care and use of la-
boratory animals of the National Institutes of Health.
The protocol was approved by the Ministry of Health
“General Direction of animal health and veterinary drug”
(Authorization 621/2015). In particular, animal care was
in compliance with Italian regulations on the protection
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of animals used for experimental and other scientific
purposes (D.lgs 26/2014).
Induction of EAE
After anesthesia, induced with an anesthetic cocktail
composed of tiletamine plus xylazine (10 ml/kg, intra-
peritoneally), EAE was actively induced using myelin
oligodendrocyte glycoprotein peptide (MOG)35–55
(MEVGWYRSPFSRVVHLYRNGK; % peak area by HPLC
≥95, AnaSpec, EGT Corporate Headquarters, Fremont,
CA, USA), according to Paschalidis et al. [28]. Mice were
immunized subcutaneously with 300 μl/flank of the emul-
sion consisting of 300 μg MOG35–55 in PBS mixed with an
equal volume of complete Freund’s adjuvant containing
300 μg heat-killed M. Tubercolosis H37Ra (Difco Labora-
tories Sparks, MD, USA). Immediately after MOG35–55 in-
jection, the animals received an intraperitoneal injection
of 100 μl B. Pertussis toxin (Sigma-Aldrich; 500 ng/
100 μl), repeated 48 h later. The disease follows a course
of progressive degeneration, with visible signs of pathology
consisting of flaccidity of the tail and loss of motion of the
hind legs.
Experimental design
Mice were randomly allocated into the following groups
(n = 30 total animals):
Naive group (n = 10)—mice did not receive MOG35–55
or other treatment;
EAE group (n = 10)—mice subjected to EAE as de-
scribed above;
EAE + hPDLSC group (n = 10)—at the onset of disease
signs that normally occurs approximately 14 days after
immunization with MOG35–55, EAE mice were subjected
to a single intravenous injection into the tail vein with
hPDLSCs (106 cells/150 μl).
hPDLSCs from the five donor lines were randomly
assigned to each animal given that they showed similar
phenotypic and morphological features as well as growth
and multidifferentiation ability.
Animals were observed every 48 h for signs of EAE
and weight loss. At the end of the experiment, which oc-
curred at day 56 after EAE induction, all animals treated
with hPDLSCs were euthanized with intraperitoneal
Tanax (5 ml/kg body weight).
Furthermore, spinal cord and brain tissues were sam-
pled and processed in order to evaluate parameters of
the disease.
Clinical disease score and body weight evaluation
The first measurement of clinical disease score was
taken on the day of EAE induction (day 0), and all the
subsequent measurements were recorded every 48 h
until sacrifice. Clinical score was evaluated using a
standardized scoring system [29] as follows: 0 = no
signs; 1 = partial flaccid tail; 2 = complete flaccid tail; 3 =
hind limb hypotonia; 4 = partial hind limb paralysis; 5 =
complete hind limb paralysis; 6 =moribund or dead ani-
mal. Animals with a score ≥5 were sacrificed to avoid ani-
mal suffering.
In addition, the first measurement of body weight was
taken on the day of EAE induction (day 0), and all the
subsequent measurements were recorded every 48 h
until sacrifice. The variation in body weight has been
expressed compared to the day of EAE induction (day
0); also the value has been expressed as mean ± SEM of
all animals for each experimental group.
Luxol Fast Blue
To show myelin and phospholipids in histological sections,
Luxol Fast Blue (LFB) staining was performed according to
the manufacturer’s protocol (Bio-Optica, Milan, Italy). The
staining provides myelin in turquoise blue, neurons and
glial nuclei in pink/violet and Nissl substance in pale pink.
Light microscopy
At 56 days after EAE induction, spinal cords were sam-
pled from the cervical region to the lumbar region, fixed
in 10 % (w/v) in PBS-buffered formaldehyde, embedded
in paraffin and then cut into 7 μm sections. The sections
were deparaffinized with xylene, rehydrated, and stained
with hematoxylin and eosin (H&E) to be studied by op-
tical microscope (Leica microscope ICC50HD).
Immunohistochemical evaluation
After deparaffinization with xylene, sections of spinal
cord samples were hydrated. Detection of glial fibrillary
acidic protein (GFAP), interleukin (IL)-1β, IL-10, CD4
and CD8α was carried out after boiling in citrate buffer
0.01 M pH 6 for 4 min. Endogenous peroxidase was
quenched with 0.3 % (v/v) hydrogen peroxide in 60 %
(v/v) methanol for 30 min. Nonspecific adsorption was
minimized by incubating the section in 2 % (v/v) normal
goat serum in PBS for 20 min.
Sections were incubated overnight with:
 anti-GFAP monoclonal antibody (1:50 in PBS v/v;
Cell Signaling Technology);
 anti-IL-1β polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc);
 anti-IL-10 (1:100 in PBS v/v; Santa Cruz
Biotechnology, Inc);
 anti-CD4 polyclonal antibody (1:50 in PBS v/v; Santa
Cruz Biotechnology, Inc);
 anti-CD8α polyclonal antibody (1:50 in PBS v/v;
Santa Cruz Biotechnology, Inc).
Endogenous biotin or avidin binding sites were
blocked by sequential incubation for 15 min with biotin
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and avidin (DBA, Milan, Italy), respectively. Sections
were washed with PBS and incubated with secondary
antibody. Specific labeling was detected with a biotin-
conjugated goat anti-rabbit IgG and avidin–biotin perox-
idase complex (Vectastain ABC kit, VECTOR). The im-
munostaining was developed with peroxidase substrate
kit DAB (Vector Laboratories, Inc.) (brown color) and
counterstaining with hematoxylin (blue background).
To verify the binding specificity, some sections were
also incubated with only the primary antibody (no sec-
ondary) or with only the secondary antibody (no pri-
mary). In these cases, no positive staining was found in
the sections, indicating that the immunoreaction was
positive in all the experiments carried out.
All sections were obtained using light microscopy
(LEICA DM 2000 combined with LEICA ICC50 HD
camera). Leica Application Suite V4.2.0 software was
used as the image computer program to acquire immu-
nohistochemical pictures.
Western blot analysis
All the extraction procedures were performed on ice
using ice-cold reagents. In brief, spinal cord and brain
tissues were suspended in extraction buffer containing
0.32 M sucrose, 10 mM Tris-HCl, pH 7.4, 1 mM EGTA,
2 mM EDTA, 5 mM NaN3, 10 mM 2-mercaptoethanol,
50 mM NaF, and protease inhibitor tablets (Roche Ap-
plied Science, Monza, Italy), and they were homogenized
at the highest setting for 2 min. The homogenates were
chilled on ice for 15 min and then centrifuged at 1000 g
for 10 min at 4 °C, and the supernatant was collected to
evaluate the content of cytoplasmatic proteins.
The pellets were suspended in the supplied complete
lysis buffer containing 1 % Triton X-100, 150 mM NaCl,
10 mM Tris-HCl, pH 7.4, 1 mM EGTA, 1 mM EDTA
protease inhibitors (Roche), and then were centrifuged
for 30 min at 15,000 g at 4 °C. Then, supernatant con-
taining nuclear extract was collected to evaluate the con-
tent of nuclear proteins. Supernatants were stored at –
80 °C until use. Protein concentration in homogenate
was estimated by Bio-Rad Protein Assay (Bio-Rad, Segrate,
Italy) using BSA as standard, and 30 μg of cytosol and nu-
clear extract from each sample were analyzed.
Proteins were separated on sodium dodecyl sulfate-
polyacrylamide minigels and transferred onto PVDF
membranes (Immobilon-P Transfer membrane, Milli-
pore), blocked with PBS containing 5 % nonfat dried
milk (PM) for 45 min at room temperature, and subse-
quently probed at 4 °C overnight with specific antibodies
for tumor necrosis factor (TNF)-α (1:500; Cell Signaling
Technology), Nrf2 (Santa Cruz Biotechnology, Inc),
FOXP3 (1:50; Cruz Biotechnology, Inc), cleaved-caspase
3 (1:500; Cell Signaling Technology), p21 (1:1000;
Millipore), p53 (1:1000; Abcam), brain-derived neurotrophic
factor (BDNF; 1:200; Santa Cruz Biotechnology, Inc), and
nerve growth factor (NGF; 1:250; Abcam) in 1× PBS, 5 %
(w/v) nonfat dried milk, 0.1 % Tween-20 (PMT). HRP-
conjugated goat anti-mouse IgG or HRP-conjugated goat
anti-rabbit IgG were incubated as secondary antibody
(1:2000; Santa Cruz Biotechnology Inc) for 1 h at room
temperature. To ascertain that blots were loaded with
equal amounts of protein lysates, they were also incubated
with antibody for GAPDH HRP Conjugated (1:1000; Cell
Signaling Technology). The relative expression of protein
bands was visualized using an enhanced chemilumines-
cence system (Luminata Western HRP Substrates, Milli-
pore) and protein bands were acquired and quantified
with ChemiDoc™ MP System (Bio-Rad) and a computer
program (ImageJ software), respectively.
Blots are representative of three separate and reprodu-
cible experiments. The statistical analysis was carried
out on three repeated blots performed on separate
experiments.
Statistical evaluation
GraphPad Prism version 6.0 program (GraphPad Software,
La Jolla, CA, USA) was used for statistical analysis of
the data.
The factors under investigation were the time elapsed
and the mRNA expression for MTT assay and the mesen-
genic differentiation, respectively. Data are expressed as
means and standard deviation of the recorded dependent
variables: the optical density (MTT assay) and mRNA ex-
pression (osteogenic, adipogenic and chondrogenic differ-
entiation). The differences among the levels of the two
factors under investigation were evaluated performing
four distinct two-way analysis of variance tests, one for
each experiment. Tukey tests were applied for pairwise
comparisons. A value of p < 0.05 was considered statisti-
cally significant in all tests.
The results for clinical disease score, body weight and
western blot analysis were statistically analyzed using
one-way analysis of variance followed by a Bonferroni
post hoc test for multiple comparisons. A p value less
than or equal to 0.05 was considered significant. Results
are expressed as the mean ± SEM of n experiments.
Results
Morphological investigations of hPDLSCs
Primary cultures of hPDLSCs at second passage, observed
by light microscopy, were stained with Toluidine blue.
Adherent cells to glass cover slips showed a spindle-
shaped morphology with elongated cytoplasmic pro-
cesses (Fig. 1a).
Evaluation of proliferation ability of hPDLSCs
The proliferation rate and viability of the hPDLSCs was
analyzed trough the MTT assay at passage 2. The
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Fig. 1 (See legend on next page.)
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examination of the acquired data showed a significant
exponential cell growth during all times examined
(Fig. 1b).
Cytofluorimetric characterization of hPDLSCs
The expression of surface molecules CD13, CD29,
CD44, CD73, CD90, CD105, CD146, and CD166, and of
pluripotency-associated markers OCT3/4, SOX2, and
SSEA4 were analyzed in xeno-free cultured hPDLSCs
(Table 1). The hPDLSCs were negative for the subse-
quent markers CD14, CD34, CD45, CD117, CD133,
CD144, CD271, and HLA-DR.
Mesengenic differentiation of hPDLSCs
Confluent living cells were induced to osteogenic differ-
entiation, and after 3 weeks the cells were stained with
Alizarin Red S to visualize the calcium deposits. The
hPDLSCs showed a characteristic arrangement; the cells
were detached from the bottom well and several areas of
high levels of mineralization related to bone nodule were
evident (Fig. 1c). The analysis of transcripts RUNX-2
and ALP confirmed the ability of the hPDLSCs towards
osteogenic differentiation (Fig. 1d). To evaluate the adi-
pogenic differentiation of hPDLSCs, the cellular mono-
layer was stained with Oil Red O and observed by light
microscopy. Adipogenic-induced cells showed the well
evident intracellular lipid droplets as single or grouped
(Fig. 1e). These data were supported by upregulation,
evaluated through real-time PC,R of the transcripts
FABP4 and PPARγ, molecules that influence the bio-
logical pathway of adipogenesis (Fig. 1f ). hPDLSC pellets
cultured for 3 weeks under chondrogenic conditions
showed strong Alcian blue staining (Fig. 1g), indicating
abundant extracellular matrix proteoglycans and glycos-
aminoglycans. Moreover, hPDLSCs expressed high levels
of chondrogenic differentiation-related genes, such as
ACAN and COL2A1 (Fig. 1h).
Clinical score and body weight
Clinical disease score as well as body weight measure-
ments were assessed as parameters of the disease. EAE
is a well-characterized, validated and recognized model
of MS in the mouse, which mimics the main features of
the disease, including paralysis, weight loss, demyelin-
ation, inflammation in the CNS and the breakdown of
the blood–brain barrier (BBB). Animals suffering from
EAE tend to reduce their body weight as a result of an-
orexia and deficient fluid uptake. During the course of
EAE, changes in body weight also reflect disease severity.
Mice often lose a small amount of weight on the day fol-
lowing immunization. This appears to be due to the ef-
fects of the administered adjuvant and pertussis toxin.
The weight loss continues with the progression of EAE
(See figure on previous page.)
Fig. 1 a Toluidine blue staining of primary cultures of hPDLSCs observed by light microscopy. The cells show mainly a spindle-shaped appearance
with long cytoplasmatic processes, euchromatic nuclei with one or more nucleoli and rough endoplasmic reticulum profiles. Original magnification:
40×. b Proliferation rate is assessed by MTT assay in five hPDLSCs grown with xeno-free medium. The results are expressed as mean ± SEM of three
independent experiments, and five replicates for each experimental point. The proliferation rate is measured as the absorbance detected at 650 nm
OD. c The hPDLSCs, induced to osteogenic differentiation and stained with Alizarin Red S, show a characteristic arrangement; after 4 weeks the cells
break off from the bottom plate and several areas of high levels of mineralization referred to as bone nodules are evident. Original magnification: 10×.
d The bar graph shows mRNA levels, determined by real-time PCR, of osteo-related genes, i.e., alkaline phosphatase (ALP) and Runt-related transcription
factor-2 (RUNX2) at 7 days of culture. e Adipogenic commitment has been evaluated by the appearance of oil-red O-positive lipid vacuoles. Original
magnification: 40×. f The adipo-related genes, i.e., fatty acid binding protein 4 (FABP4) and peroxisome proliferator-activated receptor γ
(PPARγ), analyzed by real-time PCR are shown. g Alcian blue staining of the chondrogenic pellets obtained from hPDLSCs indicating the
chondrogenic differentiation. h Effect of chondro-inductive medium on the expression of chondrogenic differentiation-related genes, such
as aggrecan (ACAN) and collagen type II (COL2A1), was analyzed by real-time PCR. **p < 0.05. Scale bars = 10 μm. For each experiment a
representative image has been shown
Table 1 Cytofluorimetric analysis of xeno-free Human periodontal
ligament stem cells cultured at the second passage; the data are
representative of five separate experiments
Stemness markers Oct 3/4 97.2 ± 1.3 %
Sox-2 98.4 ± 1.8 %
SSEA-4 97.3 ± 1.6 %
Surface markers CD 13 96.1 ± 1.3 %
CD 29 97.1 ± 3.2 %
CD 44 95.2 ± 2.1 %
CD 73 96.2 ± 1.3 %
CD 90 93.1 ± 3.1 %
CD 105 97 ± 2.9 %
CD 146 96 ± 2.8 %
CD 166 95 ± 1.2 %
Hematopoietic markers CD 14 Not detected
CD 34 Not detected
CD 45 Not detected
CD 117 Not detected
CD 133 Not detected
CD 144 Not detected
CD 271 Not detected
HLA-DR Not detected
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severity, most likely due to paralysis and reduced food
intake as well as high production of pro-inflammatory
cytokines during the acute phase of inflammation. Our
results showed that, as expected, mice belonging to the
naive group showed a normal increase in body weight
(change = +5.5 g). On the contrary, after EAE induction,
a significant body weight loss was observed in EAE mice
(–6.12 g). However, a slight body weight loss was found
in the EAE + hPDLSC group (–1.50 g) compared with
the naive group (Fig. 2b). Also, EAE animals showed a
grading of disease with a mean clinical score of 3.05,
while mice administered with hPDLSCs revealed a lower
grade of disability with a mean clinical score of 1.05.
Naive animals did not show motor deficits (Fig. 2a).
These results suggest that treatment with hPDLSCs
ameliorates clinical severity and improves functional re-
covery of EAE mice.
hPDLSCs improve histopathology of EAE
The improvement in clinical score after hPDLSC admin-
istration could reflect decreased inflammatory cell infil-
tration into the CNS. Therefore, to identify the effect of
hPDLSC treatment on the inflammatory cell influx, sec-
tions of spinal cords from EAE mice were stained with
Fig. 2 Clinical score, body weight, H&E and LFB. Mice were immunized with MOG35–55 and monitored every 2 days for clinical disease score of
experimental autoimmune encephalomyelitis (EAE) and body weight gain/loss for 56 days. a Normal, naive mice did not display motor deficit.
EAE mice displayed a grading of disease with a mean clinical score of 3.05, while mice treated with human periodontal ligament stem cells
(hPDLSCs) revealed a lower grade of disability with a mean clinical score of 1.05. The measure of clinical disease score is expressed as mean ± SEM
of all measurements of each experimental group. ****p < 0.0001. b The variation of body weight has been expressed compared to day of EAE
induction (day 0) as mean ± SEM of all animals for each experimental group. Naive mice showed a normal increase in body weight. On the
contrary, a significant body weight loss was observed in EAE mice, whereas a relevant body weight gain was found in hPDLSC-treated mice.
****p < 0.0001. hPDLSC treatment improved inflammatory cell infiltration caused by EAE. The severity of the damage was evaluated 56 days after
EAE induction by H&E staining. c Naive mice did not show histological alterations in the spinal cord tissues. d H&E staining for EAE mice displayed
a wide area of infiltrating cells (arrows) confirming the important role of the cellular components that undergoes degenerative conditions. e Conversely,
treatment with hPDLSCs led to a complete resolution of inflammatory cells infiltration. g In addition, EAE untreated animals exhibited remarkably reduced
myelin in the spinal cord (area in brackets), whereas naive mice did not show demyelination plaques (c and f). h Moreover, treatment with hPDLSC
reduces demyelination and axonal loss in EAE mice with an intense LFB positive staining (see area in brackets)
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H&E and LFB in order to detect inflammatory cell infil-
tration and demyelination, respectively, at 56 days after
EAE induction.
Naive mice did not show histological alterations in the
spinal cord tissues (Fig. 2c). Notable damage was ob-
served in the EAE mice, as demonstrated by the pres-
ence of a wide area of infiltrating inflammatory cells
such as lymphocytes and polymorphonuclear cells in the
white matter of spinal cord, confirming the important
role of the cellular components that undergo degenera-
tive conditions (Fig. 2d). Treatment with hPDLSCs in-
stead led to a reduction in inflammatory cell infiltration,
suggesting a protective effect on nervous tissues
(Fig. 2e).
As EAE is a demyelinating disease, hPDLSC treatment
was also evaluated for the protective action on myelin
sheath integrity by LFB staining. Compared to naive
mice (Fig. 2f ), EAE untreated animals exhibited remark-
ably reduced myelin and axonal structures in the spinal
cord (Fig. 2g). Consistently, corroborating this evidence,
other authors have reported myelin and axonal loss
along different white matter tracts in EAE mice, display-
ing a significant loss in LFB staining. In parallel, our evi-
dence showed that treatment with hPDLSCs reduced
demyelination and axonal loss in EAE mice with an in-
tense LFB-positive staining (Fig. 2h).
Overall quantitative analysis performed on sections of
spinal cord observed with an optical microscope at 20×
showed that the percentage of area occupied by the mye-
lin was about 0.017 % in EAE mice while in EAE +
hPDLSC mice it was estimated at about 16,014 %. These
images are representative of at least three experiments.
The values shown are the mean of three different fields
observed.
hPDLSCs modulate production of Treg cells, CD4 and
CD8α production
Regulatory T (Treg) cells are characterized by the ex-
pression of the transcription factor Forkhead box P3
(Foxp3). Treg cells play a pivotal role in keeping the in-
flammatory T cells, e.g., Th1 and Th17, in check and in
maintaining self-tolerance and immune homeostasis.
To assess whether treatment with hPDLSCs was able
to modulate the production of Treg cells, we evaluated
expression of the transcription factor Foxp3 by western
blot analysis. We observed no high expression of Foxp3
in animals subjected to EAE as well as in naive ones,
while hPDLSC administration increased its expression
(Fig. 3a). This observation has special relevance if we
consider that CD4 T-cell expression is involved in cell-
mediated immunity and in the pathogenesis of MS, with
the destruction of the axonal myelin sheath in several
areas of the CNS and spinal cord mediated mainly by
self-reactive CD4 T cells. Immunohistochemical analysis
carried out in spinal cord sections showed a positive
staining for CD4 as well as for CD8α in EAE mice
(Fig. 4b and e). Conversely, a negative staining for CD4
and CD8α was found in EAE mice administered with
hPDLSCs (Fig. 4c and f) and in the naive group (Fig. 4a
and d see densitometric analysis Fig. 6).
hPDLSCs modulate the inflammatory pathway
Modulation of inflammatory mediators in mouse spinal
cord, particularly with regard to two important cytokines
altered in the MS patients’ profile, was investigated to
understand and assess the effects of hPDLSC treatment
on molecular mechanisms of inflammation. For this rea-
son, the expression levels of IL-1β and TNF-α in spinal
cord samples were quantified by immunohistochemical
and western blot analysis.
Visibly, our results showed a negative staining for IL-1β
in spinal cord sections from naive mice (Fig. 4g) as well as
for EAE mice treated with hPDLSCs (Fig. 4i), while EAE
mice that did not receive pharmacological treatment dis-
played positive staining for this pro-inflammatory cytokine
(Fig. 4h see densitometric analysis Fig. 6).
By western blot analysis there was a considerable in-
crease in TNF-α release over the course of EAE as evi-
denced in samples collected from EAE mice. On the
contrary, reduced expression of TNF-α was observed in
mice that received hPDLSC administration. TNF-α ex-
pression was not observed in naive animals (Fig. 3b).
A negative immunolocalization for IL-10 as an anti-
inflammatory cytokine was found in spinal cord sections
of EAE mice not treated with hPDLSCs (Fig. 4k); when
hPDLSCs were given, on the contrary, IL-10 expression
was kept at high levels, preserving tissues damaged by
EAE (Fig. 4l). Naive mice showed negative staining for
IL-10 (Fig. 4j see densitometric analysis Fig. 6).
Effects of hPDLSCs on Nrf2 and GFAP expression
Astrocytes are the major glial cell population within the
CNS. After severe activation, astrocytes secrete various
neurotoxic substances and express an enhanced level of
GFAP, which is considered a marker protein for astro-
gliosis. With the aim to investigate whether hPDLSCs
can modulate astrocytic activation during EAE, spinal
cord sections were stained with an anti-GFAP antibody.
Mice subjected to EAE exhibited positive immunolocal-
ization for cytosolic GFAP (Fig. 5b), compared to the
naive group (Fig. 5a). Treatment with hPDLSCs signifi-
cantly reduced the degree of positive staining for GFAP
(Fig. 5csee densitometric analysis Fig. 6).
These results were correlated with the expression of
Nrf2, a transcription factor that binds to a short antioxi-
dant response element, found in the promoters of a
number of detoxification genes including those involved
in redox homeostasis. The induction of Nrf2-mediated
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transcription, particularly in astrocytes, has been shown
to protect against neurotoxicity from a variety of insults.
Western blot analysis showed a basal level of Nrf2 ex-
pression in spinal cord samples obtained from naive
mice. EAE mice did not show expression of Nrf2, but it
was increased by treatment with hPDLSCs (Fig. 3c).
hPDLSCs enhance neurotrophic factor release and restore
BBB vascular endothelium after EAE induction
By western blot analysis we have detected NGF as well
as BDNF expression in brain samples in order to dem-
onstrate whether neuroprotective effects could be due to
release of neurotrophic factors. The results clearly
showed that EAE induction caused a decreased NGF ex-
pression, while, under the same damaging conditions,
hPDLSC administration increased NGF levels (Fig. 5d).
Likewise, our results indicate that hPDLSC administra-
tion following EAE enhanced BDNF levels, showing the
same trend as the abovementioned neurotrophic factors
(Fig. 5e). Naive mice also showed a basal level of NGF as
well as BDNF expression (Fig. 5d and e).
During EAE the recruitment of inflammatory cells into
the CNS parenchyma is accompanied by the breakdown
of the BBB. Thus, in order to evaluate whether BBB
breakdown is accompanied by the loss or alterations of
tight junction (TJ)-associated molecules from the BBB,
Fig. 3 Western blot analysis for FOXP3, tumor necrosis factor (TNF)-α, Nrf2, cleaved caspase 3, p53 and p21. a Representative western blot
showing no significant Foxp3 expression in spinal cord tissues from experimental autoimmune encephalomyelitis (EAE) mice as well as in the
naive group. Foxp3 levels were appreciably increased in tissues from EAE mice administered with human periodontal ligament stem cells
(hPDLSCs). **p < 0.0066 vs naive; **p < 0.0038 vs EAE. b Also evident is a notable increase in TNF-α release in samples collected 56 days after EAE
induction, attenuated by administration of hPDLSCs. Naive mice did not show expression of TNF-α. *p < 0.0148 vs naive; *p < 0.0192 vs EAE. c
Western blot analysis for Nrf2 showed a basal level of Nrf2 expression in samples obtained from naive mice. EAE mice did not show expression of
Nrf2, while treatment of mice with hPDLSCs significantly increased Nrf2 expression. *p < 0.0282 vs naive; **p < 0.0096 vs EAE. Western blot analysis
for d p53 and e p21 showed a significant expression of p53 as well as p21 in samples collected 56 days after EAE induction when compared to
the naive group. Conversely, levels of p53 and p21 were clearly reduced by administration of hPDLSCs. **p < 0.0018, **p < 0.0061 vs naive; *p < 0.0395
vs EAE; **p < 0.0052 vs naive; *p < 0.0060 vs EAE. f The activation of cleaved caspase 3 was evaluated. EAE caused a significant increase in
cleaved caspase 3 expression. On the contrary, treatment with bioactive hPDLSCs prevented the EAE-induced caspase 3 expression.
****p < 0.0001 vs naive; ****p < 0.0001 vs EAE. GAPDH was used as the internal control. ND not detectable
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we investigated the claudin-5 expression by western blot
analysis. A basal level of claudin-5 was found in brain
samples collected from naive mice. Brain levels of clau-
dins were increased in animals treated with hPDLSCs
compared to EAE untreated mice (Fig. 5f ).
hPDLSC treatment inhibits EAE-induced apoptosis
Finally, we evaluated the degree of apoptosis associated
with EAE, testing the role of hPDLSCs in attenuating
cell death.
At 56 days after EAE, proteins in the mitochondrial
p53 pathway and one of its target genes, p21, were de-
tected by western blot analysis. p53 is able to induce
apoptosis both by controlling the translation of pro-
apoptotic p53-checked mediators and by nontranscrip-
tional mechanisms, including upregulation of pro-
apoptotic proteins and downregulation of anti-apoptotic
mediators. EAE mice showed a significant expression of
these markers, when compared to the naive group. Con-
versely, their expression was reduced by administration
of hPDLSCs (Fig. 3d and e).
As known, sequential activation of caspases plays a cen-
tral role in the execution phase of cell apoptosis, leading to
programmed cell death by cleavage of cellular substrates.
By western blot analysis, we evaluated the activation of
cleaved caspase 3 in spinal cord tissues. Cleaved caspase 3
levels were appreciably increased in the spinal cord from
mice subjected to EAE. On the contrary, treatment with
hPDLSCs completely prevented EAE-induced cleaved
caspase 3 expression. In naive animals cleaved caspase 3
expression was not observed (Fig. 3f ).
Discussion
This study aimed to investigate an alternative source of
MSCs as a new treatment for autoimmune and neurode-
generative diseases such as MS.
Fig. 4 Immunohistochemical evaluation for CD4, CD8α, IL-1β and IL-10. CD4 and CD8α expression reveals higher tissue levels of these markers in
experimental autoimmune encephalomyelitis (EAE)-affected mice (b, 20×, B1 magnification, 40×; e, 20×, E1 magnification, 40×) compared to the
human periodontal ligament stem cell (hPDLSC)-treated group (c, f). Spinal cord specimens from naive mice did not stain for CD4 as well as for
CD8 (a, d). Increased IL-1β tissue localization in EAE mice was reported (e, h). On the contrary, reduced expression of IL-1β was observed in mice
that received hPDLSCs (i). g The immunohistochemical analysis showed that no positive staining for IL-1β was observed in the tissues obtained
from naive mice. k EAE sections did not stain for IL-10 antibody. l Positive IL-10 expression levels were found in the EAE group treated with
hPDLSCs (arrows; l, 20×, L1 magnification, 40×). j Naive mice showed negative staining for IL-10
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Recently, we reported an innovative xeno-free culture
system for the expansion of hPDLSCs demonstrating cell
phenotype and genomic stability, essential elements to
conform to cell-based therapy [14, 30].
The need to operate under strict Good Manufacturing
Procedure and demonstrate feasibility and safety are the
goals for cell-based therapy in clinical application [31, 32].
The multipotent capacity and the immunomodulatory
properties both in vitro and in vivo of hPDLSCs make
these cells a more accessible cell niche than bone
marrow-derived stem cells for cell-based therapy of im-
mune and inflammation-related diseases [33]. Moreover,
hPDLSCs express the SDF-1a/CXCR4 complex, playing
an essential role in homing of hematopoietic stem/
progenitor cells [26, 34, 35] and driving the cells to
the injury site. hPDLSCs do not express HLA-II DR
[36], they display low immunogenicity, and can be
used in autologous, allogenic and xenogenic trans-
plantation. Thus, the possibility to derive pluripotent
MSCs from an easily accessible, young and renewable
cell source, such as human periodontal stem cells,
could: i) dramatically reduce the quantity and quality
issues involved in the use of adult tissue-derived
MSCs; ii) prevent the need for constant donor recruit-
ment (indeed the periodontal ligaments can be ob-
tained from routine oral surgery); and iii) reduce
potential risks from the use of multiple donors—in
fact it could be desirable to bank the cells in an au-
thorized structure.
Our data demonstrated that intravenous injection of
hPDLSCs into mice immunized with MOG35–55 at the
disease onset significantly improves clinical features such
as disability score as well as body weight loss, which are
well correlated with the severity of the pathology.
In agreement with earlier studies that MSCs limit de-
myelination in MS [37, 38], we found by performing
histological evaluations of stained sections of the spinal
cord that there were fewer inflammatory cell infiltrates
Fig. 5 Immunohistochemical evaluation for GFAP, and western blot analysis for nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF) and claudin-5. Immunohistochemical evaluation for GFAP tissue expression reveals an increased GFAP tissue localization in experimental
autoimmune encephalomyelitis (EAE) mice (b) compared to the naive group (a). On the contrary, reduced expression of GFAP was observed in
mice that received human periodontal ligament stem cells (hPDLSCs) (c). NGF and BDNF levels were appreciably increased in brain samples taken
from mice administered with hPDLSCs, while mice subjected to EAE showed reduced levels of these neurotrophic factors (d, e). *p < 0.0103 vs
naive; **p < 0.0065 vs EAE; **p < 0.0022 vs naive; **p < 0.0017 vs EAE. A basal level of claudin-5 production was found in brain samples collected
from naive mice. Brain levels of claudin-5 increased in animals treated with hPDLSCs (f) more than in EAE mice. *p < 0.0251, **p < 0.0022 vs naive;
*p < 0.0114 vs EAE. GAPDH was used as the internal control
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and significantly less axonal loss in hPDLSC-treated
mice.
Our evidence also demonstrated that hPDLSCs dis-
played notable immunomodulatory and anti-inflammatory
capabilities. Regarding the molecular and cellular mechan-
ism underlying EAE, firstly we looked at the state of acti-
vation of the immune system by evaluating the expression
of CD4 and CD8α cells. Cells of both the innate and adap-
tive immune system initialize the neurodegenerative
process via different effector molecules such as cytokines
or reactive species [39]. As expected, we observed that
both CD4 and CD8α detections were apparent in un-
treated EAE mice, while hPDLSCs show the capability to
counteract the release of cytotoxic T cells.
These data have been further confirmed in hPDLSC-
treated mice with a high and significant Foxp3 detection, as
an indirect marker of Treg (also known as CD4+/FoxP3+)
cell presence. Treg cells play a key role in controlling im-
mune responses after a successfully defeated infection or
to prevent autoimmune diseases [40, 41]. Therefore, treat-
ment with MSCs can play a crucial role in protection
against undesired T-cell activation and autoimmune dis-
ease by promoting Treg cell production. It seems that
the beneficial effects of hDPLSCs on animals subjected
to EAE could be due to their inherent properties to har-
ness inflammatory cell infiltration, suppress inflamma-
tory mediator production—as confirmed by a significant
decrease in TNF-α expression as well as IL-1β over the
course of treatment—and regulate immune tolerance by
increasing the production of anti-inflammatory cyto-
kines such as IL-10.
Moreover, inflammatory mediators have also been
identified in the initiation of BBB breakdown. These me-
diators act via promoting the disruption of the TJ assem-
bly, leukocyte recruitment and directly damaging the
microvasculature. Among the various components of the
BBB, the TJ claudin proteins are the most widely studied,
and are critical for maintaining the BBB structural integ-
rity and permeability [42]. The disruption of the cere-
brovascular claudin-5 has been strongly correlated with
the dynamic event of BBB breakdown [43]. In our study,
we found that EAE induces changes in claudin-5 expres-
sion, and hPDLSCs modulate claudin-5 expression and
control TJ permeability.
It is well known that astrocytes, the most abundant
population of glial cells, are essential for brain homeo-
stasis and maintenance and maturation of the BBB [44],
but they are also capable of secreting inflammatory factors
which aggravate the damage. Thus, we have demonstrated
that EAE induced a notable increase in immunostaining
for GFAP, considered as a marker of astrocytic reactivity,
that in turn was significantly inhibited in the hPDLSC-
treated group.
In addition, we evaluated the expression of Nrf2,
known as the main transcription factor that regulates
cellular defense mechanisms through antioxidant re-
sponse elements in normal tissues [45]. The induction of
Nrf2, particularly in astrocytes, has been shown to pro-
tect against neurotoxicity from a variety of injuries; in
fact, several of the genes commonly regulated by Nrf2
have been implicated in protection from neurodegenera-
tive conditions [46]. Our data showed that hPDLSC
Fig. 6 Densitometric analysis for CD4, CD8α, interleukin (IL)-1β, IL-10 and glial fibrillary acidic protein (GFAP). For immunohistochemical images,
densitometric analysis was carried out to quantify and highlight significant differences among experimental groups. p value < 0.05 was considered
significant. ND not detectable
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treatment leads to an upregulation of Nrf2 expression.
In response, a protective action of Nrf2 on astrocytes oc-
curs causing a downregulated GFAP expression.
Moreover, studies have revealed that apoptotic cell
death of oligodendrocytes and/or neurons contributes to
axonal injury and to other pathological events leading to
neurological deficits linked to MS [47, 48]. In light of
this, we studied the role of hPDLSCs on apoptosis. Spe-
cifically, we investigated a possible role of p53 and one
of its target genes, p21, involved in the cell death
process. p53 is an extremely important protein in deter-
mining cell fate decisions and its activation can result in
the transcriptional induction of target genes that regu-
late apoptosis [49]. In line with these findings, EAE mice
showed high levels of p53 and p21. On the contrary,
hPDLSC treatment downregulated their expression.
Downstream pathways leading to intrinsic and extrinsic
activation of the caspase proteases have been thoroughly
described in EAE. Therefore, we evaluated the expression
of cleaved caspase 3, and found that hPDLSCs inhibited
EAE-induced apoptosis by decreasing the level of cleaved
caspase 3. Therefore, we believe that hPDLSCs have the
capability to interfere with EAE-induced neuronal cell
death, attenuating or even preventing the activation of
molecular pathways triggered by the injury.
Looking at all these results, we hypothesized that
hPDLSC treatment may exhibit neuroprotection via
activation of neurotrophic mediators which regulate
crucial processes such as axonal growth and synaptic
plasticity in CNS [50]. Interestingly, we found that
hPDLSC administration increased the expression levels
of NGF and BDNF factors.
Conclusion
In light of the achieved results, we propose transplantation
of hPDLSCs as a putative novel tool for treatment of auto-
immune and neurodegenerative diseases such as MS.
These cells could have considerable implication for fu-
ture therapies for MS, and this study may represent the
starting point for further investigations.
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